Biotech Values

[ghmm]

Unless Turing only acquired US rights for Daraprim, was there even anything in Clinton's proposal that would stop this type of price increase?

It seems politicians like to play to what is popular and I worry that some of the innovation could be lost with excess regulaton.

One argument I didn't see made about the Daraprim situation is the total cost to the health care system would still be quite small. Considering the intent and cost of the increase would be paid by insurance/government the uproar is more about perception rather than economic impact.

Additionally while not immediate I imagine capitalism would play in and the price increase would draw competitors/innovators. The PAH (which I think is an excessively crowded field now) is a good example of high prices drawing competitors and now we are getting to the point where generics are entering.

A fair criticism of Shkreli is he is following a strategy he was publicly critical of.